The Catch-Up Visit: Three Things Out of Twelve
Ms. R is a 58-year-old marketing manager presenting for a 'catch-up' visit after 4 years without care. BMI 32 kg/m2; BP 138/86 and 136/84; A1c 6.2%; LDL 128 mg/dL; HDL 44 mg/dL; no diabetes or ASCVD. She has a 22 pack-year smoking history and quit in 2015. Her father had an MI at 52; her mother has type 2 diabetes. At age 50, colonoscopy showed two tubular adenomas (6 mm and 8 mm) with no high-grade dysplasia, and no surveillance has been done since. She has never received Tdap as an adult, has had no influenza vaccine this season, and asks whether she 'needs the HPV shot.' She is motivated but says she can only handle 'two or three things' today and wants to know what matters most.
1. She asks you to name the two or three highest-yield actions for today. What do you choose, and how do you justify leaving the rest for later?
Read the worked answer
Rank by benefit realized within her time horizon, not by how abnormal the number is.
- Colorectal surveillance colonoscopy -- schedule now. Two tubular adenomas under 10 mm with no villous histology or high-grade dysplasia place her in the low-risk adenoma category, for which repeat colonoscopy is recommended at 7-10 years, not 3. She is at year 8, so she is due -- but this is a scheduling item, not an emergency. Reasoning matters here: reflexively labeling any adenoma 'high risk, 3-year interval' would over-treat, while a 10-year default would under-surveil her.
- Low-dose CT lung cancer screening. Age 58, 22 pack-years, and quit in 2015 (within 15 years) meet eligibility criteria. This is the single item most likely to change her mortality, and the visit is also the moment to reinforce continued abstinence.
- Vaccines she can complete in one visit: influenza (seasonal), Tdap if never received as an adult, and recombinant zoster (age 50+). Low effort, high completion.
Answer her HPV question directly: routine vaccination is through age 26, and shared clinical decision-making applies at 27-45; at 58 it is not recommended. Saying so builds credibility for the recommendations you are making.
Deferred, with a stated plan: stage 1 hypertension (home BP log started today, review in 4-6 weeks), prediabetes and statin discussion at a dedicated follow-up. Explicitly naming the deferred items and when they will be addressed is what keeps a motivational visit from becoming a dropped ball.
2. How do you manage her A1c of 6.2% with BMI 32, and would you start metformin today?
Read the worked answer
A1c 6.2% is prediabetes, and lifestyle is first-line for her. The Diabetes Prevention Program showed roughly 58% reduction in progression with 7% weight loss and 150 min/week of activity -- a larger effect than metformin's ~31%.
Would I start metformin? Metformin is reasonable to consider in prediabetes when there is BMI 35 or higher, age under 60, prior gestational diabetes, or a rising A1c despite lifestyle change. She meets the age criterion and has an A1c at the upper end of the prediabetes range, but her BMI is 32 -- below the usual threshold. So: lifestyle now, no metformin today, with an explicit contract to revisit.
Monitoring plan: recheck A1c in 6 months (sooner if she develops symptoms), not annually, because she is at the top of the range and actively changing behavior. Weight and waist at each visit; a home BP log covers two problems at once.
What would change my answer: if A1c is unchanged or higher at 6 months, or weight loss stalls, metformin is a reasonable add. Also flag that starting a statin can modestly raise glycemia -- do not let a small A1c drift after statin initiation be misread as lifestyle failure.
3. She has no ASCVD. Walk through your statin decision, including what you would do if she is reluctant.
Read the worked answer
Estimate risk, then look for risk enhancers that move a borderline decision.
Her 10-year atherosclerotic risk by pooled cohort equations sits in the borderline-to-intermediate range (roughly 6-8%): age 58, systolic BP 138, HDL 44, nonsmoker, no diabetes, LDL 128. That zone is a shared decision-making zone, not an automatic prescription.
Risk enhancers present: family history of premature ASCVD (father with MI at 52 qualifies -- premature in a male is under 55). That single factor tips a borderline case toward treatment, and it also makes a 'risk calculator said no' answer inadequate.
Recommendation: moderate-intensity statin (e.g., atorvastatin 20 mg or rosuvastatin 10 mg), aiming for at least a 30% LDL reduction, after a conversation that quantifies benefit and addresses her concerns. Because her 10-year risk is not high, the expected absolute benefit is modest -- say so honestly rather than overstating.
If she declines: a coronary artery calcium score is the appropriate tiebreaker. A score of 0 supports deferring in many patients -- but in a former smoker with a strong family history, a zero score should lower, not eliminate, concern; a score above 0 supports treatment. Deferring entirely without either a statin or a calcium score is the option I would not choose. Document the conversation either way.